GHK-Cu Research# GHK-Cu research spans both laboratory and limited human studies: Wound healing : Accelerated wound closure in animal models and small human studies Skin rejuvenation : Human studies demonstrating improved skin thickness, elasticity, and collagen density with topical application Hair growth : Studies showing increased hair follicle size and proliferation Gene modulation : Comprehensive genomic studies mapping its effects on ~4,000 genes Anti-fibrotic effects : Research suggesting reduction of scar tissue formation GHK-Cu benefits from some human data in dermatological applications and a longer history of commercial use, though large-scale clinical trials remain limited
Together, these peptides support both physical and emotional aspects of hormone and sexual health, helping restore balance and connection in daily life
Standard Cagrilintide Monotherapy Chart CAGRILINTIDE ESCALATION PROTOCOL Week 1-4: [0.6 mg] Tolerance Assessment Week 5-8: [1.2 mg] Efficacy & Safety Review Week 9+: [2.4 mg] Maintenance Monitoring Theoretical Combination Dosing Chart For cagrilintide dosage with tirzepatide , a theoretical combination chart might look like: COMBINATION PROTOCOL (THEORETICAL) TIRZEPATIDE CAGRILINTIDE Week 1-4: 2.5 mg None Week 5-8: 5.0 mg None Week 9-12: 7.5 mg None Week 13-16: 7.5 mg 0.6 mg Introduction Week 17-20: 10 mg 1.2 mg Week 21+: 12.5 mg 2.4 mg Optimization This staged approach minimizes the risk of overwhelming gastrointestinal side effects while allowing for individualized dose optimization
High serum homocysteine levels may also be important in the pathogenesis of colon cancer, diabetic retinopathy, and other diseases
Research suggests that this peptide helps block the transformation of non-fatty foods into body fat, making it harder for the body to store new weight
